Table 1

DEAB rescue of cdx4−/− embryos requires exposure during gastrulation

Stage exposedTime exposed, hpfMutant embryos with increased gata1/total mutantsMutant embryos with increased gata1, %Degree of rescue
None N/A 0/23 None 
50%-90* 5.5-9 12/19 63 2+ 
50%-1 ss 5.5-10.3 23/24 96 2+ 
90%-1 ss* 9-10.3 18/21 86 1+ 
1 ss-5 ss* 10.3-11.7 2/25 Scant 
50%-5 ss 5.5-11.7 21/23 91 3+ 
60%-10 ss* 6-14 8/8 100 3+ 
90%-5 ss 9-11.7 9/9 100 2+ 
90%-10 ss 9-14 10/10 100 1+ 
5 ss-10 ss* 11.7-14 0/6 None 
Stage exposedTime exposed, hpfMutant embryos with increased gata1/total mutantsMutant embryos with increased gata1, %Degree of rescue
None N/A 0/23 None 
50%-90* 5.5-9 12/19 63 2+ 
50%-1 ss 5.5-10.3 23/24 96 2+ 
90%-1 ss* 9-10.3 18/21 86 1+ 
1 ss-5 ss* 10.3-11.7 2/25 Scant 
50%-5 ss 5.5-11.7 21/23 91 3+ 
60%-10 ss* 6-14 8/8 100 3+ 
90%-5 ss 9-11.7 9/9 100 2+ 
90%-10 ss 9-14 10/10 100 1+ 
5 ss-10 ss* 11.7-14 0/6 None 

Embryos from incrosses of cdx4+/− heterozygotes were treated with DMSO or DEAB at various stages of early development. (5.5 hpf = 50% epiboly, 6 hpf = 60% epiboly, 9 hpf = 90% epiboly, 10.3 hpf = 1 ss, 11.7 hpf = 5 ss, and 14 hpf = 15 ss) The total number of mutant embryos in 2- to 3-treated groups were pooled for each incubation period. Embryos were incubated in DEAB (2 × 10−5M) and compared with control embryos incubated in DMSO to evaluate the degree of gata1 rescue. Each data point represented pooling of several (2-4) experiments. The degree of rescue was scored based on the number of gata1+ cells present in comparison to control embryos for that experiment. A full rescue was scored as 3+ and reflected a maximal increase of gata1+ cells as depicted in Figure 4D. When only a few more cells were present in comparison to the vehicle-treated control embryos, these embryos were scored as 1+ rescue. The level of rescue was deemed intermediate or 2+ if the number of gata1+ cells was less than maximal, or if there were mixed levels of rescue among the total number of mutant embryos scored.

N/A indicates not applicable.

*

Treatment groups depicted in Figure 5.

Close Modal

or Create an Account

Close Modal
Close Modal